We’ve spent the past year on Post-Hoc Live talking about existential moments for US biotech — the downturn, the recovery, China, MFN and more. On Wednesday’s show, we’re joined by one of the leading industry veterans sounding the alarm.
Jeremy Levin has seen biopharma from practically every vantage point — he’s led dealmaking in big pharma, founded biotechs and taken the big-picture perspective as chairman of BIO. Like many experienced biopharma leaders, he’s worried about US policy and he’s worried about China.
At 11:30 am ET, I’ll talk with Dr. Levin about what the biggest problems have been, and what solutions US policymakers should put in place. (He also has a new book out where he talks about many of these issues.)
You can join us live on YouTube here. Or add us to your Google or Outlook calendar to get a reminder before we go live.
See you soon!











